Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BPH GlobalASX:BP8 Gross Margin % is 5.99% as of Jun. 2026, which is 62% below its 10-year median of 15.93. The stock has 7 warning signs investors should review. Among 940 Drug Manufacturers companies, BPH Global ranks worse than 97.98% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. BPH Global's Gross Profit for the
six
months ended in Jun. 2026 was A$0.12 Mil. BPH Global's Revenue for the
six
months ended in Jun. 2026 was A$2.07 Mil. Therefore, BPH Global's Gross Margin % for the quarter that ended in Jun. 2026 was 5.99%.
The historical rank and industry rank for BPH Global's Gross Margin % or its related term are showing as below:
ASX:BP8'
s Gross Margin % Range Over the Past 10 Years
Min: -16 Med: 15.93 Max: 22.68
Current: -2.8
During the past 13 years, the highestGross Margin % of BPH Global was 22.68%. The lowest was -16.00%. And the median was 15.93%.
ASX:BP8's Gross Margin % is ranked worse than 97.98% of 940
companies
in the Drug Manufacturers industry
Industry Median: 48.515
vs ASX:BP8: -2.80
BPH Global had a gross margin of 5.99% for the quarter that ended in Jun. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for BPH Global was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
BPH Global had a gross margin of 5.99% for the quarter that ended in Jun. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
BPH Global Gross Margin % Related Terms
BPH Global Gross Margin % Historical Data
* Premium members only.
The historical data trend for BPH Global's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BPH Global's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BPH Global Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BPH Global's Gross Margin % distribution charts can be found below:
* The bar in red indicates where BPH Global's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
BPH Global (ASX:BP8) has a Gross Margin % of 5.99% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on BPH Global and its competitors. This is 62% below median its historical median of 15.93. According to the industry distribution chart, BPH Global ranks #921 out of 940 companies in the Drug Manufacturers industry, placing it in the top 98%.
Is BPH Global's Gross Margin % too high?
BPH Global's current Gross Margin % of 5.99% is 62% below median its 10-year median of 15.93. The Drug Manufacturers industry median Gross Margin % is 48.52. BPH Global's value of 5.99% is 87.7% below this industry median. Based on the distribution chart, BPH Global ranks #921 out of 940 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does BPH Global's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, BPH Global ranks #921 out of 940 companies for Gross Margin %. This places BPH Global in the lower half of its industry. The industry median Gross Margin % is 48.52. BPH Global's value of 5.99% is 87.7% below this benchmark. While the company's 10-year median is 15.93 vs. the industry median of 48.52, BPH Global has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.52, based on 940 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BPH Global's current Gross Margin % of 5.99% is 87.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on BPH Global and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BPH Global's current Gross Margin % is 5.99%, which is 62% below median its own 10-year median of 15.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BPH Global stock overvalued right now?
BPH Global (ASX:BP8) has a current Gross Margin % of 5.99%. The current Gross Margin % is 5.99%, which is 62% below median its 10-year median of 15.93 and 87.7% below the Drug Manufacturers industry median of 48.52. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For BPH Global (ASX:BP8), the current Gross Margin % is 5.99% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BPH Global Ltd is a plant-focused biotechnology company with a focus on producing foods, health, and cosmetic products that deliver Traditional Chinese Medicine (TCM)-based health outcomes. It focuses on the research, development, production, and commercialization of TCM products, including bird's nest, seaweeds, and sea plants, which serve as sustainable plant-based protein sources and ingredients for food, nutrition, healthcare, cosmetics, and personal care industries. The company's geographical segment includes Australia, Indonesia, and China. The company's products comprise raw and processed bird's nest, sea grapes (Caulerpa lentillifera), and other seaweeds and sea plants.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BP8 has been successfully added to your 
